middle.news
Radiopharm’s clinical pipeline advances despite a tightening cash position
4:18pm on Wednesday 30th of September, 2026 AEST
•
Biotechnology and Pharmaceuticals
Read Story
Radiopharm’s clinical pipeline advances despite a tightening cash position
4:18pm on Wednesday 30th of September, 2026 AEST
Key Points
A$56.3 million total comprehensive loss
A$52.8 million operating cash outflow
A$4.1 million cash at 30 June 2026
Research and development spending rose to A$50.0 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE